Showing 81-90 of 1747 results for "".
2017 Tax Cuts and Jobs Act: What You Need to Know
https://practicaldermatology.com/topics/practice-management/2017-tax-cuts-and-jobs-act-what-you-need-to-know--vmyiwowa/18348/OJM Group principal Carole Foos, CPA provides an overview of the Tax Cuts and Jobs Act, which was signed in to law at the end of 2017. She discusses key provisions affecting individual physicians and medical practices, and offers advice to consider when planning for 2018 and beyond. Click here to reTips for dealing with patients and the media offered by Dr. Joel Schlessinger
https://practicaldermatology.com/topics/practice-management/tips-for-dealing-with-patients-and-the-media-offered-by-dr-joel-schlessinger/19155/In an increasingly connected world, business professionals must be aware of how negative customer experiences can quickly and easily be shared through the internet and social media. Dermatology is no different and Dr. Joel Schlessinger has heard of many cases in which a practice's reputation has sufAs New Jersey Goes, So Goes the Nation?
https://practicaldermatology.com/topics/practice-management/as-new-jersey-goes-so-goes-the-nation/20515/New Jersey's doctor gift ban may be the tip of the iceberg.SCALE 2024: Dr. Joel Cohen Interviews Dr. Saranya Wyles on Exosomes
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-joel-cohen-interviews-dr-saranya-wyles-exosomes/26364/Saranya Wyles, MD, PhD, joins Joel Cohen, MD, to discuss her research on exosomes at Music City SCALE.SCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. John H. Joseph on Clinical Trials for Injectables
https://practicaldermatology.com/conferences/scale-2024/scale-2024-listen-dr-joel-cohen-interviews-dr-john-h-joseph-clinical-trials-injectables/26414/John H. Joseph, MD, joins Joel Cohen, MD, to discuss his work on clinical trials for neuromodulators and filler products at Music City SCALE.Clinical Conversations: Risks vs Benefits of JAK Inhibitors
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-risks-vs-benefits-of-jak-inhibitors/20108/Clinical data for JAK inhibitors show clear benefits for many patients. But these drugs are associated with certain risks and class warnings. Matt Zirwas, MD and Adelaide Hebert, MD describe how they weigh risks, educate patients, and optimize long-term management.Journal Club: Treating Itch and Lessons from the IL-4 and IL-13 Blockade
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-treating-itch-and-lessons-from-the-il-4-and-il-13-blockade/27025/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Matthew Zirwas, MD, about how evaluations of itch can lead to treatment for atopic dermatitis, and his Journal of Drugs in Dermatology article "Unexpected Clinical Lessons Learned From IL-4 and IL-13 Blockade."Juvederm Approved for Lips, CoolMini Applicator Cleared
https://practicaldermatology.com/topics/psoriasis/juvederm-approved-for-lips-coolmini-applicator-cleared/18828/In this edition, a look at Allergan's Juvederm Voluma XC approval for lips an Zeltiq's CoolMini applicator for treatment of the sub mental area. Plus, there's new data for secukinumab in psoriatic arthritis (PSA) and Kathleen Sebelius has joined the Board of Directors of Dermira.From SDPA: JAKs, Black Boxes, and What It All Means
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-jaks-black-boxes-and-what-it-all-means/26286/Practitioners shouldn’t fear Janus kinase (JAK) inhibitors for their patients when appropriate, according to a wide-ranging expert chat at the 2024 SDPA Annual Summer Conference in San Diego. The conversation featured Matthew Zirwas, MD, a dermatologist with DOCS Dermatology, and Amy Spizuoco, DO, FJournal Club: Oral JAK Inhibitors in Moderate-to-Severe AD
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-oral-jak-inhibitors-moderate-severe-ad/24539/Peter Lio, MD, talks with Robert Sidbury, MD, MPH, a dermatologist at Seattle Children's Hospital, about nuanced differences in guideline-recommended use of oral JAK inhibitors in pediatric patients with moderate-to-severe atopic dermatitis (AD) provided in the Annals of Allergy, Asthma, and Immunol